Our Eyes Are on Reata Pharmaceuticals Today

Eye on Reata Pharmaceuticals
Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's ataxia (FA) - a rare genetic disease that causes difficulty walking, loss of sensation in the legs and arms . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.